Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

25.64 +1.59 (+6.63%)

Streaming Delayed Price Updated: 12:46 PM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Volume	148,985
Open	24.42
Bid (Size)	25.51 (100)
Ask (Size)	25.76 (300)
Prev. Close	24.05
Today's Range	24.24 - 26.77
52wk Range	11.51 - 29.80
Shares Outstanding	33,816,459
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Performance

YTD	-3.2%	-3.2%
1 Month	+1.2%	+1.2%
3 Month	+14.3%	+14.3%
6 Month	+42.6%	+42.6%
1 Year	+42.0%	+42.0%

More News

PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment ↗

December 03, 2025

Via Stocktwits

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

December 03, 2025

From Pharvaris N.V.

Via GlobeNewswire

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now ↗

December 02, 2025

Via The Motley Fool

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Via The Motley Fool

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Via The Motley Fool

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Via The Motley Fool

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Via The Motley Fool

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

Via The Motley Fool

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Via The Motley Fool

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Pharvaris N.V.

Via GlobeNewswire

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

November 10, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

October 23, 2025

From Pharvaris N.V.

Via GlobeNewswire

This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

October 15, 2025

Via Benzinga

Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress ↗

August 12, 2025

Via Chartmill

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 24, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

July 22, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Proposed Public Offering of Ordinary Shares

July 22, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

July 10, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

June 27, 2025

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

June 16, 2025

From Pharvaris N.V.

Via GlobeNewswire

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?

Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.

What exchange does Pharvaris N.V. - Ordinary Shares trade on?

Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?

The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market

What is the current price of Pharvaris N.V. - Ordinary Shares?

The current price of Pharvaris N.V. - Ordinary Shares is 25.64

When was Pharvaris N.V. - Ordinary Shares last traded?

The last trade of Pharvaris N.V. - Ordinary Shares was at 01/07/26 12:46 PM ET

What is the market capitalization of Pharvaris N.V. - Ordinary Shares?

The market capitalization of Pharvaris N.V. - Ordinary Shares is 867.22M

How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?

Pharvaris N.V. - Ordinary Shares has 867M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.